Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Syndax Pharmaceuticals (SNDX) Equity Average (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Equity Average for 11 consecutive years, with $53.1 million as the latest value for Q1 2026.

  • For Q1 2026, Equity Average fell 78.88% year-over-year to $53.1 million; the TTM value through Mar 2026 reached $53.1 million, down 78.88%, while the annual FY2025 figure was $176.4 million, 58.12% down from the prior year.
  • Equity Average hit $53.1 million in Q1 2026 for Syndax Pharmaceuticals, down from $90.0 million in the prior quarter.
  • Across five years, Equity Average topped out at $523.0 million in Q1 2024 and bottomed at $53.1 million in Q1 2026.
  • Average Equity Average over 5 years is $332.3 million, with a median of $379.6 million recorded in 2023.
  • Year-over-year, Equity Average surged 69.27% in 2022 and then tumbled 78.88% in 2026.
  • Syndax Pharmaceuticals' Equity Average stood at $402.8 million in 2022, then increased by 13.39% to $456.7 million in 2023, then fell by 28.34% to $327.3 million in 2024, then plummeted by 72.49% to $90.0 million in 2025, then plummeted by 40.99% to $53.1 million in 2026.
  • According to Business Quant data, Equity Average over the past three periods came in at $53.1 million, $90.0 million, and $136.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.